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a  b  s  t  r  a  c  t
CONTEXT:  Although  breast  cancer  is  a  common  cancer,  Pregnancy  associated  breast  cancer  is  uncom-
mon.  Adjuvant  chemotherapy  administered  intrapartum  has  been  resolved  to be  safe from  the  second
trimester.
OBJECTIVE:  To review  cases  of pregnancy  associated  breast  cancer  managed  with  adjuvant  intrapartum
chemotherapy.
PATIENTS  AND  METHOD:  Gravid  patients  diagnosed  with  breast  cancer  had  chemotherapy  administered
by  a slow  infusion  protocol  at 3 weekly  interval  from  the second  trimester  till  4  weeks  to expected  date
of  delivery.  Obstetric  scans  were  done  to monitor  fetal  growth  and  development.  Requisite  surgery  was
carried  out intrapartum  and  postpartum.
RESULTS:  There  were  three  cases  of pregnancy  associated  breast  cancer  Age range  32–33 years,  mean
32.5  years.  Two  cases  presented  in  the  second  trimester  while  one  presented  in  the  third  trimester.
The  second  case  had  overt  metastatic  disease  and  was  grave  in  respiratory  distress.  Histology  showed
invasive  lobular  carcinoma  in two  cases  and  extensive  intraductal  carcinoma  with  invasive  component
in  the  third.  Immunohistochemistry  showed  triple  negative  in  the ﬁrst case  and  hormone  positive  in
the  third  case.  Wide  local  excision  was  done  for a 3 cm lump  in  the  ﬁrst  case  and  mastectomy  postpar-
tum in the  third  case.  but  had  no  surgery.  Doxorubicin  and  cyclophosphamide  was  administered  three
weekly  from  the  second  trimester  up to  32  weeks  and  continued  postpartum.  Taxanes  was  administered
afterwards.  The  grave  clinical  state  of  the second  case  was  markedly  improved  with  the  ﬁrst  cycle  of
chemotherapy  instituted.  All  cases  had spontaneous  vaginal  delivery  with  good  apgar  scores.  Children
had  normal  developmental  milestones.  First  case  with  breast  conservation  is  clinically  disease  free,  the
second  case  demised  postpartum  from  disease  progression  while  the  third  had  a mastectomy  and  is on
cue for  radiotherapy.
CONCLUSION:  Adjuvant  intrapartum  chemotherapy  had a successful  outcome  with  birth  of normal  babies
with  normal  developmental  milestones  in  our  miniseries.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Management of pregnancy associated breast cancer in a
eveloping country. The role of chemotherapy
Pregnancy associated breast cancer has been acceptably deﬁned
s breast cancer occurring during pregnancy or up to one year
ostpartum [1]. Although pregnancy associated breast cancer is
he second commonest diagnosed malignancy in pregnancy, it is
till a rare occurrence at 1 in 3000 pregnant women [1]. The tradi-
ional view of a poorly prognostic cancer has transited to survival
 This research work ‘Management of pregnancy associated breast cancer in a
eveloping country. The role of chemotherapy’ is authentic
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reativecommons.org/licenses/by-nc-nd/4.0/).of the disease being seen at par with nonpregnant cases, multiple
studies reporting equivalent survivals in early cases when matched
with nonpregnant patients [2–4]. Nevertheless some studies have
dissented reporting advanced cases with lymph node involvement
and a poorer prognosis with these patients [5,6]. With the trend to
record improved survival following breast cancer diagnosis, man-
agement of intrapartum breast cancer places the health of the
mother at conﬂict with the foetus. This was the classical basis for
proponents of termination of pregnancy to allow treatment (Fig. 1)
[7,8].
The administration of chemotherapy in pregnancy was classi-
cally dogged by controversy due to the fear of possible induction of
teratogenicity in the foetus. Current evidence showing the safety
of chemotherapy has been successfully illustrated in several series
[9,10]. Expectedly, absence of considerably large series in this
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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TFig. 1. 2nd Case on doxorobicin infusi
ncommon presentation as has been obtained with breast can-
er makes the presence of standard protocols challenging [11].
e are not aware of any published reports of its utilization in
est Africa as the majority of published reports have emerged
rom the Western world. Hence a report from West Africa where
esources are thought to be limited, encourages the routine use
f chemotherapy intrapartum for this disease thus avoiding pos-
ible spread from intrapartum delay. Additionally, the experience
ith one of the cases is unique being a gravid woman  who
resented looking grave with metastatic disease but was  ‘resus-
itated’ with the ﬁrst chemotherapy cycle (Table 1). We  review
he outcome of pregnancy associated breast cancer in the authors
ractice.
.1. Patients and methods
The subjects were patients who were presented with a breast
ump/mass in pregnancy. Following history and examination,
reast biopsy under local anaesthesia was done and specimen sent
o the pathologist to make a breast cancer diagnosis. Patients subse-
uently had abdominopelvic ultrasound scan to date the pregnancy
nd to ascertain liver involvement. Patients were counselled for
hemotherapy administered from the second trimester at three
eekly intervals. Subsequent abdominal ultrasound scans were
one before each session to monitor fetal growth. Reexcision was
one in the case for breast conservation under local anaesthesia.
atients were also receiving antenatal care from the obstetrician
ntil they fell into spontaneous labour and delivery. Following
elivery the babies were examined for any discernible malforma-
ions. Breastfeeding was omitted in the babies and treatment of the
others continued.
able 1
umour sizes and treatment modality.
Age Size of lump/cm Histology Surgery 
32 3 Invasive lobular Wide loc
32  14 Invasive lobular 
33  7 Intraductal with invasive component Mastectoalthy baby from case on observation.
1.2. Second case
A 32 years old secondary school leaver diagnosed as a T4
tumour which had taken over the whole breast with extensive peau
d’orange, nipple retraction and matted axillary lymphadenopa-
thy. Abdominal exam revealed 20 cm hepatomegaly below the
costal margin. She appeared grave and in respiratory distress.
Histopathology revealed invasive lobular carcinoma. Being in
the second trimester, she was commenced on doxorubicin and
cyclophosphamide. Her initial grave clinical state had a rapid
improvement within days of chemotherapy commencement. Four
cycles of doxorubicin was  completed intrapartum in the second and
third trimester. Spontaneous vaginal delivery occurred at 34 weeks
with birthweight 1–8 kg, good apgar scores. Baby did not require
intensive care. She had systemic progression of disease postpartum
being lost to oncology care and succumbed outside oncology care
3 months postpartum.
1.3. Results
There were three cases of breast cancer diagnosed during preg-
nancy. Ages ranged between 32–33years. The ﬁrst case was a T2
tumour (3 cm)  with no clinical axillary lymphadenopathy and no
systemic involvement. The second case was diagnosed as a T4
tumour which had taken over the whole breast with extensive peau
d’orange, nipple retraction and matted axillary lymphadenopa-
thy. Abdominal exam revealed 20 cm hepatomegaly below the
costal margin. She was  in respiratory distress. The third case had
a T3 tumour at 7 cm by 5 cm with axillary lymphadenopathy and
no systemic involvement. Histopathology revealed invasive lobu-
lar carcinoma in two cases and extensive intraductal carcinoma
with an invasive component in the third case. The ﬁrst two  cases
were diagnosed during the second trimester while the third was
diagnosed at the third trimester. Four cycles of doxorubicin and
No of intrapartum chemotherapy cycles Birth weight/kg
al excision 5 3.1
4 1.8
my 1 4.1
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yclophosphamide based chemotherapy were administered from
he second trimester for the ﬁrst and second cases and one cycle
n the third trimester in the third case. Chemotherapy was contin-
ed postpartum following a 3 week break from the expected date
f delivery. Paclitaxel was commenced following six cycles of dox-
rubicin based chemotherapy. All cases had spontaneous vaginal
elivery at 37 weeks, 34 weeks and 40 weeks respectively. Birth
eights were 3.1 kg, 1.8 kg and 4.1 kg respectively. Apgar scores
ere good with babies crying spontaneously following birth. All
he babies were healthy with no discernible malformations. The
ow birth weight baby from the second case did not require inten-
ive care. All babies have had normal developmental milestones.
he ﬁrst case had breast conservation and is disease free 5 years
ost presentation, the second case had systemic progression of dis-
ase postpartum and succumbed to the disease while the third one
ad a mastectomy postpartum and is still on chemotherapy.
. Discussion
Cancer in pregnancy is a rare event affecting up to 0.02–0.1%
f cases [12]. The age range at 32–33 years with a mean age of
2.5years is in keeping with multiple studies at 32–34 years age
ange. [3,10,13,14]. Our second case was diagnosed with metastatic
reast cancer presenting at the second trimester. Pregnancy asso-
iated breast cancer may  have a delayed diagnosis as routine
reast exam may  be skipped during antenatal care. Also, pregnancy
nduced breast changes of breast enlargement and engorgement
ay  mask the presence of a lump. However our ﬁrst case had
n earlier presentation with a T2 tumour and no axillary lym-
hadenopathy. This may  be attributed to the educational level
f the ﬁrst patient having obtained tertiary education unlike the
econd case with secondary education. Our third case had an
xtensive carcinoma in situ with invasive component predating
he pregnancy. There are reports that intrapartum pregnancy is
ften associated with more advanced forms [5,6]. It remains to be
een whether delayed diagnosis from pregnancy induced breast
hanges or distraction by the gravid abdomen may  account for
hese advanced cases rather than an inherent aggressive tendency.
Following the current standard of care, chemotherapy was
dministered from the second trimester for the ﬁrst two  patients
nd third trimester for the third case. This was  critical in reviv-
ng the second case that had presented in a grave condition being
yspneic with prostration. However she emerged ambulant with
emarkable improvement in general state of well being within days
f its commencement. We  are of the ﬁrm view that delaying the
dministration of chemotherapy would have resulted in immedi-
te adverse outcome for the second case with consequences for
he foetus. Netletton et al. had estimated the daily increased risk
f developing metastases in an untreated intrapartum breast can-
er at 0.057% [15]. Momah  et al. reported the case of a 28 years
ld that presented with a T1 tumour at ﬁrst trimester but trag-
cally rapidly progressed to metastases [16]. It is worthy of note
hat a 30 weeks delay to institution of chemotherapy existed from
resentation to administration of chemotherapy postpartum. The
xperience in our second case may  suggest that patients with preg-
ancy associated breast cancer may  not be considered too ill for
hemotherapy even when metastatic as it made the difference in
chieving a live delivery.
Berry et al. reported an initial 24 patients managed with CAF
egimen from the second trimester with no intrapartum events.
ood apgar scores, normal birthweights and immediate postpar-
um health were reported [9]. In the same updated study, Hahn et al.
ecorded successes in 57 cases with no stillbirths, miscarriages or
herapy related perinatal deaths. However three preterm deliver-
es, one subarachnoid haemorrhage from thrombocytopaenia and
[
[PEN  ACCESS
Surgery Case Reports 17 (2015) 117–120 119
one case of Downs syndrome were recorded [10]. Although 10% of
neonates in the Hahns series required mechanical ventilation from
difﬁculty with breathing [10], our miniseries did not record any
neonatal event as babies only required observation.
Rovera et al. have reported a series of a dozen patients
with all healthy babies born following adjuvant and neoadjuvant
chemotherapy. Ten of these patients had breast conserving man-
agement while mastectomy was  done in two. Nine patients were
reported to be alive and disease free after a median follow up of 20
months, range 3–52 months [11]. Our case that had breast conser-
vation is alive and disease free. Classically, pregnancy associated
breast cancer had been previously thought to be aggressive hence
a modiﬁed radical mastectomy was considered standard of care.
Berry et al. have noted that breast conservation as well as mas-
tectomy could be done for this disease successfully [9]. However
breast irradiation, a critical adjuvant for breast conservation would
have to be delayed till postpartum given the risks of fetal irradiation
[17].
3. Conclusion
Chemotherapy administered from the second trimester was  safe
in our subjects. It rapidly reversed the grave clinical state of the
2nd case in stage 4 disease with a resulting healthy life birth. An
intrapartum adverse outcome with loss of the previable foetus was
very likely if chemotherapy was  delayed.
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